152 related articles for article (PubMed ID: 38573209)
21. Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
Snaterse G; Taylor AE; Moll JM; O'Neil DM; Teubel WJ; van Weerden WM; Arlt W; Hofland J
J Steroid Biochem Mol Biol; 2024 Feb; 236():106446. PubMed ID: 38104728
[TBL] [Abstract][Full Text] [Related]
22. Canonical and Noncanonical Androgen Metabolism and Activity.
Storbeck KH; Mostaghel EA
Adv Exp Med Biol; 2019; 1210():239-277. PubMed ID: 31900912
[TBL] [Abstract][Full Text] [Related]
23. Steroidogenesis in the skin: implications for local immune functions.
Slominski A; Zbytek B; Nikolakis G; Manna PR; Skobowiat C; Zmijewski M; Li W; Janjetovic Z; Postlethwaite A; Zouboulis CC; Tuckey RC
J Steroid Biochem Mol Biol; 2013 Sep; 137():107-23. PubMed ID: 23435015
[TBL] [Abstract][Full Text] [Related]
24. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
25. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.
Mostaghel EA; Nelson PS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):243-58. PubMed ID: 18471783
[TBL] [Abstract][Full Text] [Related]
26. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
27. Effects of Etomidate on the Steroidogenesis of Rat Immature Leydig Cells.
Liu HC; Zhu D; Wang C; Guan H; Li S; Hu C; Chen Z; Hu Y; Lin H; Lian QQ; Ge RS
PLoS One; 2015; 10(11):e0139311. PubMed ID: 26555702
[TBL] [Abstract][Full Text] [Related]
28. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
[TBL] [Abstract][Full Text] [Related]
29. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Peltola KJ; Bono P; Jones RH; Vjaters E; Nykänen P; Vuorela A; Oksala R; Pohjanjousi P; Mustonen MVJ; Fizazi K; Massard C
Eur Urol Focus; 2020 Jan; 6(1):63-70. PubMed ID: 30194031
[TBL] [Abstract][Full Text] [Related]
30. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
31. Circulating steroid hormone variations throughout different stages of prostate cancer.
Snaterse G; Visser JA; Arlt W; Hofland J
Endocr Relat Cancer; 2017 Nov; 24(11):R403-R420. PubMed ID: 28924064
[TBL] [Abstract][Full Text] [Related]
32. Steroid biosynthesis and prostate cancer.
Sharifi N; Auchus RJ
Steroids; 2012 Jun; 77(7):719-26. PubMed ID: 22503713
[TBL] [Abstract][Full Text] [Related]
33. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
34. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts.
Locke JA; Nelson CC; Adomat HH; Hendy SC; Gleave ME; Guns ES
J Steroid Biochem Mol Biol; 2009 Jul; 115(3-5):126-36. PubMed ID: 19442514
[TBL] [Abstract][Full Text] [Related]
35. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
36. Endocrine treatment in prostate cancer.
Denis LJ; Griffiths K
Semin Surg Oncol; 2000; 18(1):52-74. PubMed ID: 10617897
[TBL] [Abstract][Full Text] [Related]
37. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
38. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
Cai C; Balk SP
Endocr Relat Cancer; 2011 Oct; 18(5):R175-82. PubMed ID: 21712345
[TBL] [Abstract][Full Text] [Related]
40. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
Geller J; Albert J; Vik A
Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]